The Research Network, who are developing EmstoPA, a humanised antibody fragment for the treatment of bleeding complications in patients who have received the clot buster tPA, presented their pitch for investment to a panel of judges at the BioCap Conference on Thursday 29th September at Alderley Park. The event is organised by Bionow in partnership with RSM, Appleyard Lees and Slater Heelis and is sponsored by Manchester Science Partnerships.
Head judge Gareth King from Catapult Ventures said “I am extremely grateful to my fellow judges Jim Green from Seroba, Simon Graindorge from IP Group, Oliver Sexton, from Midven and Kath Mackay from Innovate UK. We found the quality of all the pitches to be extremely high and found it difficult to select a winner but The Research Network application just edged it.”
The BioCap Company Pitching Competition is a fantastic opportunity for companies who are seeking to secure investment to present to the international life science investment community, more than 60 of whom were present at the event.
